Opinion statement Diffuse large B cell lymphoma (DLBCL) arises from extranodal organs in
about 30% of cases. Its prognosis and risk of recurrence in the central nervous system …

Secondary central nervous system (CNS) lymphoma (SCNSL) is defined by the involvement
of the CNS, either at the time of initial diagnosis of systemic lymphoma or in the setting of …

Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell
lymphoma (DLBCL). Integrating biomarkers into the CNS–International Prognostic Index …

Central nervous system (CNS) relapse affects 5% of diffuse large B‐cell lymphoma (DLBCL)
patients and portends a poor prognosis. Prophylactic intravenous high‐dose methotrexate …

PURPOSE CNS progression or relapse is an uncommon but devastating complication of
aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS …

Abstract Purpose Secondary CNS involvement (SCNS) is a profoundly adverse complication
of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall …

Central nervous system (CNS) relapse of diffuse large B-cell lymphoma remains uncommon
but catastrophic. The benefit of standalone intrathecal prophylaxis in reducing CNS …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes.
Despite the majority of patients being cured with combination chemoimmunotherapy, up to …

Central nervous system (CNS) relapse following R‐CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisolone) occurs in 2–5% of patents with diffuse large B‐cell …

Accurate and reproducible staging is crucial for management of malignant lymphomas.
Disease stage influences treatment decisions more significantly than any other clinical …